

Information analysis

Analyst:

Dr. Roger Becker, CEFA, Biologist, Phone: +49 69-71 91 838-46; roger.becker@bankm.de

Q1/09 reporting - operative records

- Record sales: €24.3 Mill. (+71%, YoY)
- Best operating result (adjusted for special effects in 2008); EBIT margin: 15.3% (+2.6%-age points, adjusted)
- Focusing on profitability - as previously announced - successfully substantiated: group result after minorities at €2.2 Mill. (+265%, adjusted; all segments are profitable)
- Positive top and bottom line contribution from nuclitec
- Liquid funds at period end: €10.8 Mill. (+47%, compared to year end)
- Our adjusted forecast 2009: sales volume unchanged at €100 Mill.; group result attributable to shareholders: €4.5 Mill. (previous: €4.2 Mill.) → Earnings/share: €1.17 (previous: €1.11)
- Foundation of a joint venture between IBt and Russian state fund for the supply of radioactive transplants (seeds) for prostate cancer patients will strengthen the sales basis outside European core regions
- Belgian securities agency requires takeover bid for IBt; an appeal at the Court of Appeal in Brussels is explicitly allowed
- Comprehensive corporate action proposed to shareholder meeting on May 20, 2009 (generation of authorized and conditional capital)

During the reporting period, the group generated revenues in the amount of €24.3 Mill., resulting in a net profit of €2.2 Mill. attributable to EZAG's shareholders. Main sales driver was again the segment „Nuclear Medicine & Industry“ (N&I) with 52% of total sales, followed by the segments „Therapy“ (28%), and „Radiopharmacy“ (20%). Benefitting from economies of scale, earnings in the segment N&I grew faster than sales (sales: +115%, earnings: +243%). For the first time after the integration of „International Brachytherapy“ (IBt) into the group, the segment „Therapy“ (sales: +30%) is clearly profitable, demonstrating the success of restructuring processes. With a significant growth of +56%, the „Radiopharmacy“ segment now seems to have exceeded the break-even point in a sustainable manner.

Based on the positive Q1 results, we perceive a strong support for our previous valuation and reiterate our fair value of €10.56. The current multiple-based valuation indicates a higher value; however, for the sake of prudence, we behave observant and await stabilization of the positive sector sentiment.

Key Financials (T€)


Year	Sales	EBITDA	EBIT	EBT	adj. Net	adj. EPS	DPS	EBIT Margin	Net Margin
2008	71,612	18,619	9,469	8,301	4,502	1.43	0.25	13.2%	6.3%
2009	100,000	14,723	9,023	7,516	4,546	1.17	0.30	9.0%	4.5%
2010	106,000	18,520	12,720	11,070	6,696	1.73	0.29	12.0%	6.3%
2011	111,300	22,595	16,695	15,345	8,774	2.26	0.43	15.0%	7.9%
2012	116,865	25,867	19,867	18,817	10,731	2.77	0.57	17.0%	9.2%

Source: BankM Research

Fair Value: €10.56

Buy

Financial figures	2009	2010	2011
EV/Sales	0.7	0.7	0.7
EV/EBITDA	5.0	4.0	3.3
EV/EBIT	8.2	5.8	4.4
P/E adj.	6.8	4.6	3.5
Price/Bookvalue	0.6	0.6	0.5
Price/FCF	n.a.	9.0	5.2
ROE	9.5	12.5	14.4
Dividend yield	3.7	5.4	7.1
Number shares (million)			3,879
Market cap / EV (million €)		31,0 / 74,6	
Free Float			57.40%
WKN			565970
ISIN			DE0005659700
Bloomberg			EUZ GY Equity
Sector			Medical Technology
Accounting			IFRS
Market segment Transparency			Regulated Market Prime Standard
Financial Year			Dec. 31
Price May 4, 2009 (XETRA-cbse)			€ 8.00



Ecker & Ziegler AG (blue/black, Performance 1 year vs. DAX Subsector MedTech (red/grey))

Source: Deutsche Börse AG

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

This document has been prepared due to a service agreement with the respective issuer. BankM – Repräsentanz der biw AG is the designated sponsor of the company's stock and, in this function, will regularly hold a trading stock or long or short positions in the company's stock. Equity investments generally involve high risks. Potential investors should take into account that share prices may fall and rise and that income from an investment may fluctuate considerably. Investors may lose some or all of the money invested. Investors make their decisions at their own risk.

Stock and Valuation

Year-to-date, EZAG's stock came down by 6.4% from €8.55 to €7.99 (XETRA close May 4, 2009). During the same period, the benchmark (DAXSUBSEC. MEDICAL TECHNOLOGY PERFORMANCE) decreased by 3.51%. Since initiation of our coverage on April 1, 2009, the share price gained 17.6%, significantly out-performing the benchmark (+9.81%). For the reported period, the annualized volatility of daily returns is at 59.67% with a mean daily trading volume of 2.700. The volatility based on 250 trading days ranks in the middle field of the peer group and is likely to decrease given the current upward trend in trading volume: with a daily average of ca. 7.250 in April, the volume reached a remarkable level for a SmallCap company like EZAG. A decreasing volatility of the stock implies a reduction of risk, which is of particular significance for private investors enjoying a limited diversification potential, only.

Regarding the positive Q1 results, we have adjusted both, our forecast for the current fiscal year and our DCF analysis (please also refer to our basic report dated April 1, 2009). We calculate an equity value of €48.8 Mill. (previous: €48.2 Mill.), translating into a price of €12.58 per share (previous: €12.42). Our peer group analysis - based on the P/E ratio for 2009 - now suggests a price of €14.23 per share (previous: €9.63). This increase in price reflects the positive performance of the comparables resulting in a median P/E multiple of 12.16 (previous: 8.70). Consistent with the methodology introduced in our basic research, we are weighting the result of the peer group analysis at 2/3 and the DCF-derived value at 1/3, returning a price of €13.76 per share.

However, the prevailing volatility in the stock markets warrants a critical assessment regarding sustainability of the peer group's price performance. Therefore, we behave observant and will adjust our fair value not until we have confidence in the stabilization of the current positive market sentiment (our next update). While we are hesitant - at this point in time - to adjust our stock valuation upwards, we perceive a strong support for our previous valuation and reiterate our fair value of €10.56.

Based on both, our fundamental analysis and a current P/E ratio of 6.84, EZAG's stock is favorably valued and a clear "buy".

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

Eckert & Ziegler AG

May 5, 2009

DCF Model

DCF analysis based on future free cash-flows 2009-2016 + Terminal Value

in T€ -		actual		Forecasting period										Terminal Value 2017+	
		2008	2009e	Phase 1				Phase 2				2016e			
				2010e	2011e	2012e	2013e	2014e	2015e						
	Growth		40%	6%	5%	5%	4%	4%	3%	3%					1%
	Basis		1	2	3	4	5	6	7	8					
	Revenues	71,612.0	100,000.0	106,000.0	111,300.0	116,865.0	121,539.6	126,401.2	130,193.2	134,099.0					
	EBIT	9,469.0	9,023.2	12,720.0	16,695.0	19,867.1	20,661.7	21,488.2	22,132.8	22,796.8					
	- Tax	3,292.0	3,158.1	4,452.0	5,843.3	6,953.5	7,231.6	7,520.9	7,746.5	7,978.9					
	+ Depreciation	9,150.0	5,700.0	5,800.0	5,900.0	6,000.0	7,292.4	7,584.1	7,811.6	8,045.9					
	+ change in long-term provisions	8,054.0	0.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0	-1,000.0					
	- changes in net working capital	-1,584.0	242.6	51.3	45.3	47.6	216.7	48.6	37.9	39.1					
	- other non-cash items	13,233.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0					
	- Capex	5,461.0	13,000.0	8,480.0	8,904.0	9,349.2	9,723.2	10,112.1	10,415.5	10,727.9					
	= Free Cash Flow	6,271.0	-1,677.6	4,536.7	6,802.5	8,516.8	9,782.7	10,390.7	10,744.6	11,096.9					
	Terminal Value														11,207.9
	Discount factor		0.89	0.80	0.71	0.64	0.57	0.51	0.45	0.40					101,889.7
	NPVs of Free Cash Flows														
	NPV of Terminal Value		n.a.	-1,497.8	3,616.6	4,841.9	5,412.6	5,551.0	5,264.2	4,860.3	4,481.9				
	Valuation														41,151.6
			Proportion of EV												
	Result of Future Cash Flows	32,530.6	44%												
	+ Result of Terminal Value	41,151.6	56%												
	= Value of the Entity	73,682.2													
	+ Cash	7,311.0													
	- LT Debt	30,242.0													
	- Minorities	1,964.0													
	Value of Equity	48,787.2													
	Price per Share	12.58													

Source: BankM Research

Peer Group Analysis

Company	Price	MarketCap (Mill.)	EPS			P/E		
			2008a	2009	2010	2008a	2009	2010
Europe								
aap Implantate AG	1.34	37.4	-0.20	0.14	0.20	neg.	9.57	6.70
Biolitec AG	3.10	32.60	0.19	0.55	0.92	16.32	5.64	3.37
Carl Zeiss Meditec AG	9.29	755.37	0.66	0.63	0.72	14.08	14.75	12.90
Pulsion Medical Systems AG	2.60	24.90	-0.08	0.33	0.54	-32.50	7.88	4.81
Stratec Biomedical Systems AG	15.15	173.10	0.54	0.90	1.21	28.06	16.83	12.52
UMS Medical Syst. Intl AG	4.25	25.57	0.54	0.66	0.77	7.87	6.44	5.52
W.O.M. World of Medicine AG	9.19	82.71	0.33	0.16	n.a.	27.85	57.44	n.a.
Wavelight AG	20.64	136.31	-0.27	0.12	0.78	-76.44	172.00	26.46
Median		60.0	0.26	0.44	0.77	14.08	12.16	6.70
Eckert & Ziegler AG	8.00	31.03	1.43	1.17	1.73	5.59	6.84	4.63
USA (for information only)								
Theragenics Corp.	0.87	29.25	0.11	0.06	0.06	7.91	14.50	14.50
North American Scientific Inc.	0.11	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Varian Medical Systems, Inc.	25.24	3,139.76	1.74	1.93	2.16	14.51	13.08	11.69

Prices as of May 4, 2009

Year	2009	2010
Implicit Price	14.23	11.56

Source: BankM Research

Specific risks related to the claim of a mandatory takeover bid for IBt

On April 28, 2009, EZAG informed via an *ad hoc* announcement, that the Belgian Securities Regulator CBFA has required Eckert & Ziegler to launch a mandatory public takeover bid for International Brachytherapy (IBt) at €3.47 per share (see our basic research, dated April 1, 2009). An appeal at the Court of Appeal in Brussels is explicitly allowed and the CBFA accepted to suspend any action until a preliminary decision is taken there. Furthermore, the CBFA acknowledged that in the event of a takeover bid, a cash offer would not be necessary and that settlement by securities would be an option.

We consider the authority's suspension of immediate actions as positive, since it could have mandated a takeover bid without additional notification. In this scenario, EZAG would have been obliged to pursue a (tedious) compensation suit with a delayed recognition of potential entitlements. The CBFA's current *modus operandi* suggests a certain degree of uncertainty regarding the legal situation.

According to management, EZAG now has the option to file an objection against the CBFA's requirement within two weeks (a rejection would not impede any appeal procedure or suspension of immediate actions) or to submit a mandatory bid within eight weeks. Management is still convinced that it has not violated any regulations of the Belgian Securities Trading Act.

Background

By means of a share contribution agreement, Eckert & Ziegler sold its implant business (BEBIG GmbH) to IBt and obtained 38.5% of common stock according to 6.75 million of a total of ca. 17 million shares. The remaining common shares (ca. 10 million) are being held by the remainder of the IBt shareholders.

Regarding the potential risk of a mandatory takeover bid, EZAG has posted a provision of €7.14 Mill. on its 2008 balance sheet. At the time of balancing the provision (*ad hoc* from March 18, 2009), the spread between the actual price of €2.48 per IBt share and the claimed takeover price of €3.47 resulted in a premium of ca. €10 Mill. (the actual risk of litigation).

At a current price of €3.15 per IBt share (May 4, 2009) - an increase by ca. 14% compared to the previous close -, EZAG would be faced with a financing requirement of €31.5 Mill. At the same time, the increase in IBt's share price results in a proportionate release of the provision mentioned above, since the premium, and with it, the litigation risk in quantitative terms is formally reduced.

In the event of a mandatory takeover bid, the current statement of the CBFA regarding the settlement option for the acquisition of IBt's remaining common stock (cash/non-cash) provides EZAG with a repertoire of alternative financing instruments (*nota bene*: in the event of a mandatory takeover bid, the provision would be completely released through income statement).

The discussed financing issue is reflected in the Executive Board's and Supervisory Board's proposals to the shareholder meeting (May 20, 2009) to

1. create new authorized capital by increasing the capital stock by up to €1.94 Mill.
2. create conditional capital by up to €40 Mill. via the issuance of convertibles

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

Eckert & Ziegler AG

May 5, 2009

Ad 1: Given a financing requirement of ca. €32 Mill. and a current price of €8.00 per EZAG share (May 4, 2009), new authorized stock alone would not suffice to meet the financing requirement; only 48.5%, i.e. €15.5 Mill., of the contingent obligation would be covered.

Ad 2: The specifications of the convertible as designed in the proposal to the shareholder meeting would provide EZAG with comprehensive exercise options, e.g. the right to deliver - in full or in part - shares and/or cash. Whether a convertible as a financing instrument to meet the requirements of a mandatory takeover bid will be accepted by the Belgian securities agency is currently beyond our knowledge.

Both of the discussed alternative financing instruments may result in a dilution of existing shareholders; the degree of dilution depends on the intrinsic value of the assets acquired in the context of a potential takeover.

Management is currently involved with legal consultation; we will pay close attention to the further course of the proceedings and will comment on current developments, timely.

Tables

P&L Q1/09 and Quarterly Forecasts 2009

Fiscal Year 31/12 • IFRS	2008a	Q1/08a	Q1/09a	Delta %*	Q2/09e	Q3/09e	Q4/09e	2009e
Total Sales	71,612.0	14,254.0	24,312.0	70.6	24,000.0	24,000.0	27,688.0	100,000.0
Cost of Sales	37,453.0	9,529.0	11,731.0	23.1	12,480.0	12,480.0	14,397.8	51,088.8
<i>% of sales</i>	<i>52.3</i>	<i>66.9</i>	<i>48.3</i>		<i>52.0</i>	<i>52.0</i>	<i>52.0</i>	<i>51.1</i>
Gross Profit	34,159.0	4,725.0	12,581.0	166.3	11,520.0	11,520.0	13,290.2	48,911.2
Distribution Expenses	15,115.0	2,978.0	4,728.0	58.8	4,800.0	4,800.0	5,537.6	19,865.6
<i>% of sales</i>	<i>21.1</i>	<i>20.9</i>	<i>19.4</i>		<i>20.0</i>	<i>20.0</i>	<i>20.0</i>	<i>19.9</i>
General & Admin. Expenses	14,609.0	2,770.0	4,293.0	55.0	4,320.0	4,320.0	4,983.8	17,916.8
<i>% of sales</i>	<i>20.4</i>	<i>19.4</i>	<i>17.7</i>		<i>18.0</i>	<i>18.0</i>	<i>18.0</i>	<i>17.9</i>
R&D Expenses	3,108.0	1,903.0	496.0	-73.9	720.0	720.0	830.6	2,766.6
<i>% of sales</i>	<i>4.3</i>	<i>13.4</i>	<i>2.0</i>		<i>3.0</i>	<i>3.0</i>	<i>3.0</i>	<i>2.8</i>
Other Operating Income	17,241.0	1,067.0	332.0	-68.9	0.0	0.0	0.0	332.0
Other Operating Expenses	8,979.0	32.0	49.0	53.1	0.0	0.0	0.0	49.0
Income from Ord. Business	9,589.0	-1,891.0	3,347.0	<i>n.a.</i>	1,680.0	1,680.0	1,938.2	8,645.2
Foreign exchange gains/losses	51.0	-148.0	377.0	<i>n.a.</i>	0.0	0.0	0.0	377.0
Other Financial Items	-171.0	14,038.0	1.0	-100.0	0.0	0.0	0.0	1.0
Financial Result	-120.0	13,890.0	378.0	-97.3	0.0	0.0	0.0	378.0
EBIT	9,469.0	11,999.0	3,725.0	-69.0	1,680.0	1,680.0	1,938.2	9,023.2
Interest Income	73.0	21.0	21.0	0.0	0.0	0.0	0.0	21.0
Interest Expenses	1,241.0	262.0	367.0	40.1	377.0	387.0	397.0	1,528.0
EBT	8,301.0	11,758.0	3,379.0	-71.3	1,303.0	1,293.0	1,541.2	7,516.2
Taxes on Income	5,264.0	3,229.0	703.0	-78.2	456.1	452.6	539.4	2,151.0
Net Profit	3,037.0	8,529.0	2,676.0	-68.6	847.0	840.5	1,001.8	5,365.2
Result from discont. Operations	-	-	97.0		-	-	-	97.0
Minorities	-1,465.0	572.0	616.0	7.7	100.0	100.0	100.0	916.0
Adjustments	0.0	0.0	0.0		0.0	0.0	0.0	0.0
Adjusted Net Profit	4,502.0	7,957.0	2,157.0	-72.9	747.0	740.5	901.8	4,546.2
<i>No. of Shares**</i>	3,143	3,143	3,548		3,879	3,879	3,879	3,879
Net Profit/Share (EPS)	1.43	2.53	0.61	-76.0	0.19	0.19	0.23	1.17

* due to special effects limited comparability, only; **for reported periods (a): Ø in circulation

Source: BankM Research

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

Eckert & Ziegler AG

May 5, 2009

Profit & Loss Account

Fiscal Year 31/12 • IFRS	08a	09e	10e	11e	12e	09e	10e	11e	12e	CAGR
in T€						y-o-y changes (%)				
Total Sales	71,612.0	100,000.0	106,000.0	111,300.0	116,865.0	39.6	6.0	5.0	5.0	13.0
Cost of Sales	37,453.0	51,088.8	54,060.0	55,650.0	57,263.9	36.4	5.8	2.9	2.9	11.2
Gross Profit	34,159.0	48,911.2	51,940.0	55,650.0	59,601.2	43.2	6.2	7.1	7.1	14.9
Distribution Expenses	15,115.0	19,865.6	19,080.0	18,921.0	18,698.4	31.4	-4.0	-0.8	-1.2	5.5
General & Admin. Expenses	14,609.0	17,916.8	16,960.0	16,695.0	17,529.8	22.6	-5.3	-1.6	5.0	4.7
R&D Expenses	3,108.0	2,766.6	3,180.0	3,339.0	3,506.0	-11.0	14.9	5.0	5.0	3.1
Other Operating Income	17,241.0	332.0	0.0	0.0	0.0					
Other Operating Expenses	8,979.0	49.0	0.0	0.0	0.0					
Income from Ord. Business	9,589.0	8,645.2	12,720.0	16,695.0	19,867.1	-9.8	47.1	31.3	19.0	20.0
Foreign exchange gains/losses	51.0	377.0	0.0	0.0	0.0					
Other Financial Items	-171.0	1.0	0.0	0.0	0.0					
Financial Result	-120.0	378.0	0.0	0.0	0.0					
EBIT	9,469.0	9,023.2	12,720.0	16,695.0	19,867.1	-4.7	41.0	31.3	19.0	20.4
Interest Income	73.0	21.0	50.0	50.0	50.0					
Interest Expenses	1,241.0	1,528.0	1,700.0	1,400.0	1,100.0					
EBT	8,301.0	7,516.2	11,070.0	15,345.0	18,817.1	-9.5	47.3	38.6	22.6	22.7
Taxes on Income	5,264.0	2,151.0	3,874.5	5,370.8	6,586.0					
Net Profit	3,037.0	5,365.2	7,195.5	9,974.3	12,231.1	76.7	34.1	38.6	22.6	41.7
Result from discontinued Operations	-	97.0	-	-	-					
Minorities	-1,465.0	916.0	500.0	1,200.0	1,500.0					
Adjustments	0.0	0.0	0.0	0.0	0.0					
Adjusted Net Profit	4,502.0	4,546.2	6,695.5	8,774.3	10,731.1	1.0	47.3	31.0	22.3	24.3
<i>For Information purposes</i>										
Depreciation	9,150.0	5,700.0	5,800.0	5,900.0	6,000.0	-37.7	1.8	1.7	1.7	-10.0
EBITDA	18,619.0	14,723.2	18,520.0	22,595.0	25,867.1	-20.9	25.8	22.0	14.5	8.6
No. of Shares*	3,143	3,879	3,879	3,879	3,879	23.4	0.0	0.0	0.0	5.4
Net Profit/Share (EPS)	1.43	1.17	1.73	2.26	2.77	-18.2	47.3	31.0	22.3	17.9
Cash Earnings (CE)/Share	6.4	2.9	3.1	3.8	4.4	-55.7	8.4	24.0	15.8	-8.9

*2008: Ø outstanding

Source: BankM Research

Cash Flow Statement

Fiscal Year 31/12 • IFRS	08a	09e	10e	11e	12e	09e	10e	11e	12e	CAGR
in T€						y-o-y changes (%)				
Net Profit	3,037.0	5,365.2	7,195.5	9,974.3	12,231.1	76.7	34.1	38.6	22.6	41.7
+ Depreciation & Amortisation	9,150.0	5,700.0	5,800.0	5,900.0	6,000.0	-37.7	1.8	1.7	1.7	-10.0
+ Chg. in long-term Provisions	8,054.0	0.0	-1,000.0	-1,000.0	-1,000.0	n.a.	0.0	0.0	0.0	n.a.
= Cash Earnings	20,241.0	11,065.2	11,995.5	14,874.3	17,231.1	-45.3	8.4	24.0	15.8	-3.9
- other non-cash items	13,233.0	0.0	0.0	0.0	0.0					
- Chg. in Net Working Capital	-1,584.0	242.6	51.3	45.3	47.6	n.a.	-78.9	-11.7	5.0	-41.9
= Operating Cash Flow	8,592.0	10,822.5	11,944.2	14,829.0	17,183.5	26.0	10.4	24.2	15.9	18.9
- Capex	5,461.0	13,000.0	8,480.0	8,904.0	9,349.2	138.1	-34.8	5.0	5.0	14.4
= Free Cash Flow	3,131.0	-2,177.5	3,464.2	5,925.0	7,834.3	n.a.	n.a.	71.0	32.2	25.8
+ Net Other Items	59.0	0.0	0.0	0.0	0.0	n.a.	0.0	0.0	0.0	n.a.
- Dividends (Previous Year)	786.0	1,110.0	1,136.5	1,673.9	2,193.6	41.2	2.4	47.3	31.0	29.3
- Payout minorities	103.0	0.0	0.0	0.0	0.0	n.a.	0.0	0.0	0.0	n.a.
+ Increase in Share Capital	0.0	3,143.2	0.0	0.0	0.0					
- Outflow from Share Buy Backs	0.0	0.0	0.0	0.0	0.0					
+/- Bank Loans	635.0	2,500.0	0.0	0.0	0.0					
= Incr. in Cash (+)/Decr. in Cash (-)	2,936.0	2,355.7	2,327.7	4,251.1	5,640.8	-19.8	-1.2	82.6	32.7	17.7

Source: BankM Research

Balance Sheet

Fiscal Year 31/12 • IFRS	08a	09e	10e	11e	12e	09e	10e	11e	12e
in T€									
Assets						% of Balance Sheet Total			
Tangible Assets	23,807.0	31,107.0	33,787.0	36,791.0	40,140.2	24%	25%	25%	26%
Other Assets	41,332.0	47,050.3	48,258.9	49,326.5	50,447.4	42%	38%	36%	34%
<i>t/o Goodwill</i>	26,907.0	26,907.0	26,907.0	26,907.0	26,907.0	27%	22%	20%	19%
Total Fixed Assets	65,139.0	78,157.3	82,045.9	86,117.5	90,587.6	66%	63%	62%	60%
Inventories	8,555.0	11,946.3	12,663.1	13,296.3	13,961.1	9%	10%	10%	9%
Accounts Receivable	13,985.0	19,528.8	20,700.6	21,735.6	22,822.4	14%	16%	16%	15%
Total Liquid Funds	7,311.0	9,666.7	11,994.4	16,245.5	21,886.2	7%	8%	9%	11%
Other Current Assets	3,808.0	5,317.5	5,636.6	5,918.4	6,214.3	4%	4%	4%	4%
Total Current Assets	33,659.0	46,459.4	50,994.7	57,195.8	64,884.0	34%	37%	38%	40%
Balance Sheet Total	98,798.0	124,616.7	133,040.5	143,313.2	155,471.7	100%	100%	100%	100%
Liabilities						% of Balance Sheet Total			
Subscribed Capital	3,250.0	3,879.0	3,879.0	3,879.0	3,879.0	3%	3%	3%	3%
Share Premium	30,316.0	33,459.2	33,459.2	33,459.2	33,459.2	31%	27%	25%	23%
Retained Earnings & Other Reserves	7,290.0	10,726.2	16,285.1	23,385.5	31,923.0	7%	9%	12%	16%
Shareholders Equity	40,856.0	48,064.3	53,623.3	60,723.7	69,261.2	41%	39%	40%	42%
Minorities	1,964.0	2,777.0	3,277.0	4,477.0	5,977.0	2%	2%	2%	3%
Group Equity	42,820.0	50,841.3	56,900.3	65,200.7	75,238.2	43%	41%	43%	45%
Provisions	16,389.0	16,389.0	15,389.0	14,389.0	13,389.0	17%	13%	12%	10%
<i>t/o Pension Provisions</i>	420.0	586.5	621.7	652.8	685.4	0%	0%	0%	0%
Other Liabilities	39,589.0	57,386.4	60,751.2	63,723.5	66,844.5	40%	46%	46%	44%
Total Liabilities	55,978.0	73,775.4	76,140.2	78,112.5	80,233.5	57%	59%	57%	55%
<i>t/o LT Liabilities</i>	30,242.0	37,837.3	38,045.8	38,113.4	38,234.5	31%	30%	29%	27%
<i>t/o ST Liab. <1Y</i>	25,736.0	35,938.1	38,094.4	39,999.1	41,999.1	26%	29%	29%	28%
Balance Sheet Total	98,798.0	124,616.7	133,040.5	143,313.2	155,471.7	100%	100%	100%	100%

Source: BankM Research

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

Eckert & Ziegler AG

May 5, 2009

Important information, disclosures and disclaimer

A. Important information

Equity investments generally involve high risks. Investors may lose some or all of the money invested. Potential investors should take into account that share prices may fall and rise and that income from an investment may fluctuate considerably. Past performance is no guarantee for future results. Investors make their decisions at their own risk.

B. Disclosures according to Section 34b of the German Securities Trading Act (WpHG) and the Ordinance on the Analysis of Financial Instruments (FinAnV):

I. Information about author, company held accountable, regulatory authority:

Responsible for the content of this document: biw Bank für Investments und Wertpapiere AG, Willich, Germany.

Author: Dr. Roger Becker, CEFA, Biologist

Regulatory authority for biw Bank für Investments und Wertpapiere AG is the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin), Graurheindorfer Straße 108, 53117 Bonn, Germany and Lurgiallee 12, 60439 Frankfurt am Main, Germany.

Issuer of the analyzed instrument is Eckert & Ziegler AG.

Notice according to sec. 4 §. 4 N° 4 FinAnV (previous publications regarding the issuer within the last 12 months):

Analyst	Date	Evaluation result	Fair Value
Dr. Roger Becker	April 1, 2009	Buy	€10.56

II. Additional Information:

1. Sources of information:

Main sources of information for the compilation of this document are publications in national and international media and information services (e.g. Reuters, VWD, Bloomberg, dpa-AFX and others), financial newspapers and magazines (e.g. Börsenzeitung, Handelsblatt, Frankfurter Allgemeine Zeitung, Financial Times and others), specialist media, published statistics, rating agencies as well as publications by peer group companies and the company itself. Furthermore talks with the management of the issuer have been held. This document was made available to the issuer before publication to ensure the accuracy of the information provided. This resulted in no/some textual changes.

2. Summary of the valuation principles and methods used to prepare this document:

BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG uses a 3-tier absolute rating model. The ratings are the evaluation results and refer to a fair value pricing reflecting a time-horizon of up to 12 months.

BUY: The calculated fair value of the company's stock is at least 15 % higher than the current market price at the time of the compilation of this document.

NEUTRAL: The calculated fair value of the company's stock lies between -15% and +15 % of the current market price at the time of the compilation of this document.

SELL: The calculated fair value of the company's stock is at least 15 % lower than the current market price at the time of the compilation of this document.

The following valuation methods are being used: Multiple-based models (Price/Earnings, Price/Cash-flow, Price/Book value, EV/Sales, EV/EBIT, EV/EBITA, EV/EBITDA), peer-group comparisons, historical valuation approaches, discount models (DCF, DDM), break-up value and sum-of-the-parts-approaches, asset-based evaluation methods or a combination of the above. The used valuation models depend on macroeconomic factors, such as interest rates, exchange rates, raw materials and on basic assumptions about the economy. Additionally, market sentiment affects the valuation of companies. The valuation is also based on expectations that might change rapidly and without notice, depending on developments specific to individual industries. Rendered evaluation results and fair values derived from the models might therefore change respectively. The evaluation results in general relate to a 12-month horizon. However, evaluation results are subject to changing market conditions and represent only the situation at a given point of time. The evaluation results and fair value prices may in fact be achieved more quickly or slowly than expected by the analysts. Also, the evaluation results and fair value prices might need to be revised upward or downward.

3. Date of first publication of this document:

May 5, 2009

4. Date and time of prices of the instruments quoted in this document:

Closing prices of May 4, 2009

5. Updates:

A specific date or time for an update of this document has not been set. The information given in this document reflects the author's judgement on the date of this publication and is subject to change without notice; it may be incomplete or condensed and it may not contain all material information concerning the company covered. It is in the sole responsibility of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG to decide on a potential update of this document.

III. Disclosures about potential conflicts of interest:

BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG's business model is based on economic relationships with issuers and equity transactions to be performed relating to the issuer's stock. BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG has entered into an agreement about the preparation of this document with the issuer that is, or whose financial instruments are, the subject of this document.

BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG (incl. subsidiaries and affiliates), the authors of this document as well as other persons that were involved in the compilation of this document or affiliated parties:

- do not have a major shareholding (shareholding exceeding 5%) of the share capital of the issuer that is, or whose financial instruments are, the subject of the analysis. Board members, directors, employees or clients of biw Bank für Investments und Wertpapiere AG possibly are holders of instruments that are mentioned in this document (or that are related to these instruments) or could become holders and could regularly trade the issuer's securities or securities based on these issues as principal or agent,
- have no other significant economic interests relating to the issuer that is, or whose financial instruments are, the subject of this analysis.

BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG was mandated as lead bank for the rights issue of Eckert & Ziegler AG conducted in January/February 2009 and, in this connection, has been party to an agreement on the provision of investment banking services with the issuer that is, or whose financial instruments are, the subject of this document.

2. In the function as a designated sponsor, BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG manages the financial instruments that are, or whose issuers are, the subject of the financial analysis on a market by placing buy or sell orders and will regularly hold a trading stock or long or short positions in the issuer's stock.

3. BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG's internal organisation is aligned with the prevention of conflict of interests in producing and distributing research reports. Possible conflicts of interests will be treated adequately. In particular, physical and non-physical boundaries were installed to keep analysts from gaining access to information that possibly could constitute a conflict of interest for the bank. biw Bank für Investments und Wertpapiere AG keeps insider registers according to sec. 15 WpHG for employees and assignees that normally have access to inside information. These registers will be transmitted to BaFin on request. Insiders' dealings according to sec. 14 WpHG categorically are prohibited. Staff members that fill a specific position and have access to inside information categorically have to disclose all dealings in financial instruments to the internal compliance department. The compliance of legal requirements and supervisory regulations is subject to continuous supervision and control of the compliance department of biw Bank für Investments und Wertpapiere AG. In this regard, the right to restrict employees' dealings in financial instruments is reserved.

4. The remuneration of the analysts mentioned above is not dependent on any investment banking transactions of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG or its affiliates. The analysts that compiled this document did not receive or acquire shares in the issuer that is, or whose financial instruments are, the subject of this document at any time. The analysts mentioned above hereby certify that all of the views expressed accurately reflect his or her personal views about the issuer and that no part of his or her compensation was, is or will be, directly or indirectly, related to the specific evaluation result or views expressed by the analyst in this document.

5. Updated information according to sec. 5 para. 4 N°. 3 FinAnV is available at: http://www.bankm.de/webdyn/138_cs_Gesetzliche+Angaben.html.

C. Disclaimer:

This document was compiled by BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG solely for informational purposes and for the personal use by persons in Germany that are interested in the company and who purchase or sell transferable securities for their own account or the account of others in the context of their trade, profession or occupation. This document neither constitutes a contract nor any kind of obligation.

This document and its content, in whole or in part, may not be reproduced, distributed, published or passed on to any other person without the prior written consent of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG.

This publication is for distribution in or from the United Kingdom only with the prior written consent of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG and only to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom or any order made there under or to investment professionals as defined in Section 19(5) of the Financial Services and Markets Act 2000 (financial promotion) order 2005 (the order) respectively in the version as amended from time to time and is not intended to be distributed or passed on, directly or indirectly, to any other class of persons.

Neither this document nor any copy of it may be taken or transmitted into the United States of America, Canada, Japan or Australia or distributed, directly or indirectly, in the United States of America, Canada, Japan or Australia or to any resident thereof.

The distribution of this document in other jurisdictions may be restricted by law, and persons who are in possession of this document have to inform themselves about any such restrictions and observe any such restrictions.

This document is not intended to be an offer, or the solicitation of any offer, or any advice or recommendation to buy or sell the securities referred to herein. This document is intended to provide information to assist institutional investors in making their own investment decisions, not to provide investment advice to any specific investor. Potential investors should seek professional and individual advice before making their investment decisions. Investment decisions must not be based on this document.

The information within this document has been obtained from sources believed by BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG to be reliable, but BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG does not examine the information to be accurate and complete, nor guarantees its accuracy and completeness. Although due care has been taken in compiling this document, it cannot be excluded that the information given is incomplete or the document contains errors. The liability of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG shall be restricted to gross negligence and wilful misconduct. All opinions expressed in this document are those of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG respectively the authors and subject to change without notice. Possible errors or incompleteness of this document may be corrected by BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG and do not constitute grounds for liability, neither with regard to indirect nor to direct or consequential damages. Only in case of failure in essential tasks, BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG is liable for simple negligence. In addition BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG does not accept any liability or responsibility for any loss arising from any use of this publication or its contents or otherwise arising in connection herewith. In any case, the liability of BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG is limited to typical, foreseeable damages and the liability for any indirect damages is excluded.

By accepting this document, the reader/user of this document agrees to be bound by all of the foregoing provisions and this disclaimer. Moreover, the user agrees not to distribute this document to unauthorized persons. The user of this document shall indemnify BankM – Repräsentanz der biw Bank für Investments und Wertpapiere AG for any damages, claims, losses, and detriments resulting from or in connection with the unauthorized use of this document.

This document is subject to the laws of the Federal Republic of Germany. Place of jurisdiction is Frankfurt am Main, Germany.

Should certain specifications of this disclaimer not be legally binding or become legally non-binding, this will have no impact on the legally binding character of this disclaimer and its other legal specifications.

PLEASE CONSIDER IMPORTANT INFORMATION, DISCLOSURES AND THE DISCLAIMER AT THE END OF THIS DOCUMENT!

Eckert & Ziegler AG

May 5, 2009

This document is not intended for use by persons resident in any jurisdiction that regulates access to such documents by applicable laws. Investment decisions must not be based on any statement in this document. Persons in possession of this document should inform themselves about possible legal restrictions and observe them accordingly. In case of uncertainty persons should not access and/or consider the content of this document in any decisions. This document is not intended for use by persons that are classified as US-persons under the United States Securities Act.

© 2009 BankM - Repräsentanz der biw Bank für Investments und Wertpapiere AG, Mainzer Landstraße 61, D-60329 Frankfurt.

biw Bank für Investments und Wertpapiere AG, Hausbroicher-Straße 222, D-47877 Willich. All rights reserved.

This document is only a translation of the legally binding German original version of May 5, 2009.